Net Sales

Q1 2025: $2,481,127 vs Q4 2024: $12,181,971 (~80% decline)

The dramatic drop in net sales is mainly due to a significant decrease in cosmetic ingredient sales (declined by 63%), which were previously a major revenue driver, compounded by reduced order volumes from key distributors in China. This sharp decline contrasted with the strong performance in Q4 2024 where rising sales in cosmetic ingredients, medical lubricants, and steady pharmaceutical sales had boosted the overall revenue. " "

Cost of Sales

Q1 2025: $1,123,076 vs Q4 2024: $5,721,584

Cost of Sales fell in line with the steep reduction in overall revenue. In Q4 2024, higher sales volume necessitated higher production and inventory costs, while the drop to a lower revenue base in Q1 2025 forced a proportional decline in costs, reflecting the tight linkage between sales volume and cost level. " "

Operating Income

Q1 2025: $610,922 vs Q4 2024: $3,646,789 (~83% decrease)

The reduction in operating income is primarily a result of the substantial fall in net sales. Although some segments such as medical lubricants and pharmaceuticals maintained momentum, the negative impact from the collapse of cosmetic ingredient orders in Q1 2025 overshadowed these improvements, leading to an overall 83% decline compared to the strong performance in Q4 2024. " "

Net Income

Q1 2025: $560,895 vs Q4 2024: $3,250,875 (~83% decline)

The net income drop parallels that of operating income; the decline is largely driven by the steep reduction in revenue from cosmetic ingredients. This erosion in earnings reflects the challenges in sustaining the momentum seen in Q4 2024, where a 12% increase in net sales had supported stronger profitability. " "

Earnings per Share (EPS)

Q1 2025: $0.12 vs Q4 2024: $0.71

The significant drop in EPS is a direct consequence of lower net income. In Q4 2024, higher earnings per share were buoyed by robust performance across multiple segments, but the revenue downturn in Q1 2025, driven chiefly by the collapse in cosmetic ingredient sales, resulted in a marked deterioration in per-share performance. " "